The Week Ahead in Biotech (Nov. 28 – Dec. 4)

By Benzinga
Benzinga
Benzinga
November 29, 2021 Updated: November 29, 2021

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-shortened week.

Shares of companies with a COVID portfolio, including a vaccine, a treatment, or both, reacted with strong moves to the upside in the truncated session on Friday.

Takeda Pharmaceutical Company Limited and Aadi Bioscience, Inc. received Food and Drug Administration nod for their Livtencity and Fyarro, respectively.

Here are the catalysts that could impact trading in the upcoming week:

Conferences

The Evercore ISI 4th Annual HealthCONx Virtual Conference: Nov. 30 – Dec. 2
Piper Sandler 33rd Annual Virtual Healthcare Conference: Nov. 29 – Dec. 2
American Epilepsy Society, or AES, 2021 Annual Meeting: Dec. 3–7, in Illinois, Chicago

PDUFA Dates

The FDA is scheduled to rule on VBI Vaccines Inc.’s biologic license application for its Sci-B-Vac meant to treat hepatitis B virus infection. The PDUFA date is scheduled for Tuesday, Nov. 30.

BeyondSpring Inc.’s NDA for plinabulin + G-CSF Combination has a PDUFA date of Tuesday, Nov. 30. Plinabulin, in combination with granulocyte colony-stimulating factor, is being studied for the prevention of chemotherapy-induced neutropenia.

CTI BioPharma Corp.’s NDA for pacritinib also has a PDUFA date of Tuesday, Nov. 30. Pacrotinib, if approved, is expected to address the unmet medical need of myelofibrosis patients with severe thrombocytopenia.

The regulator will also announce its verdict on Merck & Co.’s, Inc. supplemental BLA for Keytruda for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection. The PDUFA date is set for Saturday, Dec. 4.

Clinical Readouts/Presentations

180 Life Sciences Corp. is scheduled to present at the 2021 International Dupuytren Symposium phase 2a clinical trial data to identify the optimal dose and top line data for the recently completed phase 2b clinical trial on efficacy for patients with early-stage disease. (Wednesday, Dec. 1, at 3 pm)

Xenon Pharmaceuticals Inc. will present at the AES meeting additional data from the Phase 2b X-TOLE study of XEN1101 in ‘difficult-to-treat’ adult patients with focal epilepsy.

IPOs

IPO Quiet Period Expiries

MDxHealth SA
Mainz Biomed B.V.
Evotec SE
IO Biotech, Inc.

By Shanthi Rexaline 

© 2021 The Epoch Times. The Epoch Times does not provide investment advice. All rights reserved.


Benzinga